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Abstract Cardiovascular magnetic resonance imaging
(CMR) has become the gold standard not only for cardiac
volume and function quantification, but for a key unique
strength: non-invasive myocardial tissue characterization. Sev-
eral different techniques, separately or in combination, can
detect and quantify early and established myocardial patholog-
ical processes permitting better diagnosis, prognostication and
tracking of therapy. The authors will focus on the histological
and pathophysiological evidence of these imaging parameters
in the characterization of edema, infarction, scar and fibrosis.
In addition to laying out the strengths and weaknesses of each
modality, the reader will be introduced to rapid developments
in T1 and T2 mapping as well as the use of contrast-derived
extracellular volume for quantification of diffuse fibrosis.
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Introduction
Tissue characterization and measurement of fibrosis is a main-
stay of clinical care in respiratory medicine, nephrology and
hepatology, but in cardiology this has been limited to the few
patients who received cardiac biopsies. The emergence of
cardiovascular magnetic resonance (CMR) is changing this.
Myocardial fibrosis is inherently an important clinical param-
eter because fibrosis represents one of the hallmarks of patho-
logical remodeling of the myocardium [1–4]. CMR has
established itself over the last decade not only as the gold
standard for cardiac chamber volume and function quantifica-
tion, but also for non-invasive myocardial tissue characteriza-
tion. Its strength lies in the use of multiple parameters to
characterize myocardium. The development of imaging param-
eters for the quantification of edema, infarction and scar has
been followed by their adoption by the CMR community for
non-invasive tissue characterization, in particular in acute and
chronic myocardial infarction (MI). During an acute MI, oc-
clusion of a coronary artery territory leads to myocyte necrosis,
which spreads from the subendocardial to the subepicardial
layers (the 'wavefront phenomenon'). Without reperfusion, or
collateral blood supply, complete necrosis of the perfusion
territory distal to the occluded coronary artery ensues. The total
amount of myocardium at risk of necrosis is termed the 'area-at-
risk' (AAR). In general the resulting irreversibly injured myo-
cardium (i.e., chronic myocardial infarct) is smaller than the
AAR; furthermore, early reopening of the infarct-related artery
can interrupt this process and lead to salvage of myocardium.
This review will focus on the histological and pathophysio-
logical evidence of these imaging parameters in the character-
ization of infarction, scar and fibrosis across myocardial pathol-
ogies. The majority of animal models are based on myocardial
ischemia and infarction, therefore large amounts of histological
and pathophysiological evidence arises from the exemplar con-
ditions of acute and chronic myocardial infarction.
Fundamental Properties of Tissues
Magnetic resonance characteristics of protons vary between
tissues, depending on the configuration of atoms in the tissues.
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These inherent differences can be exploited to generate differ-
ing signals from separate tissues: T1 relaxation time (longitu-
dinal relaxation time) is determined by how rapidly protons
re-equilibrate their spins with their environment following a
radiofrequency (RF) pulse. The native (non-contrast) myocar-
dial T1 varies with water content and increases in cases of
edema, fibrosis or infiltration of the extracellular space (e.g.,
in cardiac amyloid). Inherently, it embodies composite signal
from both cells and interstitium, and varies with measurement
technique and MRI field strength. Regional difference in T1
can be visualized by T1-weighted MR sequences or directly
estimated by T1 mapping. T2 relaxation time (spin-spin
relaxation time) is determined by how rapidly the refocused
transverse signal decays after a RF pulse (in contrast to the rate
of spin dephasing, which is called T2*). T2 is shorter when
water is tightly bound to large molecules like collagen, but
longer when water is free. T2-weighted images emphasize
tissues with long T2 or in conditions like where myocardial
edema is present; new T2 mapping sequences are able to
quantify T2 directly.
Exploring Pathophysiology with T1 and T2 Imaging:
Acute Infarction
Technical advances in T1 and T2-weighted imaging have
allowed in-vivo visualization and accurate quantification of
myocardial edema, a substantial feature of myocardial infarc-
tion (MI) with ischemic and reperfusion injury. Preliminary
work by Higgins et al. in the 1980s in a dog infarct model
showed T1 and T2 elevation in infarction [5]. The observed
changes were theoretically consistent with myocardial edema
and correlated with the measurements of myocardial water
content estimated by wet-weight to dry-weight ratios. This
early work aimed to develop non-contrast methods for diag-
nosing MI but overestimated infarct size. It was not until a
decade later that T2-weighted images were clearly shown to
correspond to the area at risk (AAR) during an acute MI rather
than the eventual chronic infarct size.
In 1993, Garcia-Dorado et al. were the first to show, in an
ex-vivo dog model of both non-reperfused and reperfused
infarction, that T2-weighted images represent the AAR and
to confirm a tight relationship between myocardial T2 and
tissue water content [6]. Aletras et al. then showed that in-vivo
T2-weighted images enabled measurement of the area at risk
and compared well with fluorescent microspheres [7]. Tilak
et al. reported that T2-weighted images correspond to the area
at risk in a canine model of non-reperfused infarcts, using
first-pass perfusion during coronary occlusion as reference
[8]. More recently, Ugander et al. [9] validated T2-weighted
and pre-contrast T1-weighted images as measures of the AAR
against whole-heart microsphere reference standards.
In humans, following initial work noting that T2-weighted
images could be used to differentiate acute from chronic
myocardial infarction [10], Berry et al. [11] showed that T2-
weighted images in acute myocardial infarctions were
transmural and had hyperintense regions in the distribution
of the culprit coronary artery. Friedrich et al. recognized that
T2-weighted images could be used to image salvaged myo-
cardium in humans [12]. Carlsson et al. [13] used sestamibi
(injected prior to acute percutaneous coronary intervention
and imaged with SPECT) to validate T2-weighted images
with regard to determination of area at risk and found excel-
lent correlation, and showed that the AARwas similar on days
1–7 post MI but then decreased over 6 months. This fact alone
cements the use of CMR in clinical studies and was recently
confirmed by work at 3 Tesla byDall'Armellina and colleagues
[14]. The use of T2-weighted CMR has not been restricted to
acute infarction, but has also established itself in the diagnos-
tic pathway for investigation and characterization of myocar-
dial inflammation, infiltration and masses. This follows a
pattern of myocardial tissue characterization being used and
developed in infarction where large differences exist between
normal and abnormal tissue and dissemination into other focal
diseases, particularly scar in non-ischemic cardiomyopathies
before use for diffuse myocardial abnormalities. In a process of
incremental value rather than succession, technical devel-
opment has followed a similar pathway with T1/T2-weighted
imaging followed by late gadolinium enhancement technique,
and, more recently, quantitative T1 and T2 mapping tech-
niques. These will be discussed subsequently.
Conventional Scar Imaging by Late Gadolinium
Enhancement
Historically, myocardial scar has been visualized andmeasured
directly on histological sections using stains specific for the
connective tissue in the extracellular space [1]. However, to
allow non-invasive measurement, tracers were needed that are
confined to the extracellular space. These tracers needed to
distribute homogeneously through the extracellular space but
not enter cells; be highly water but not fat soluble; not be
adsorbed, actively transported, protein-bound or metabolized;
be non-toxic, stable and be cleared freely from the body; and
finally be easily measured. Gd-DTPA fulfills these require-
ments as a tracer; it diffuses rapidly from the vascular space
into most extracellular tissue fluid, but not to the intracellular
space, leading to the term ‘extracellular contrast agent’. Gad-
olinium is a paramagnetic metal and because it has the most
unpaired electrons [15], is the most efficient T1 relaxing agent,
and also shortens T2 and T2*. In the presence of gadolinium,
T1 of tissues is potently shortened, resulting in increased signal
on T1-weighted images and appearing bright on a T1 inversion
recovery image. The relaxation rate (R1 or 1/T1) is directly
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proportional to the concentration of gadolinium. Gadolinium-
based contrast agents are safe, with serious adverse events
being extremely rare with an incidence less than 1 in
100,000. Its safety profile and effect on the fundamental prop-
erties of T1 make it an ideal MR contrast agent.
Pathophysiological Basis of GadoliniumContrast Imaging
To understand the pathophysiological basis of gadolinium con-
trast imaging, the pharmacokinetics of Gd-DTPA need to be
considered. Following an intravenous bolus, gadolinium enters
the myocardium down a concentration gradient (“wash-in
phase”), and later, as the gadolinium has been cleared from the
blood pool, it returns to the blood pool down the reversed
concentration gradient (“wash-out phase”). This occurs over
seconds to minutes in healthy myocardium, where cells are
tightly packed and cell membranes are intact. In acutely infarct-
ed tissue, these kinetic effects are delayed due to changes in
coronary flow rates, capillary permeability, and functional cap-
illary density [16]. Furthermore, the volume of distribution is
larger due to ruptured cell membranes allowing Gd-DTPA to
passively diffuse into the cellular compartment [17]. Combined,
Gd-DTPA accumulates and lingers in the infarcted tissue giving
shorter T1s. In chronic infarct (i.e., established scar), the volume
of distribution is larger because of a significant reduction in
living myocytes, which are replaced by a dense, hydrated colla-
gen matrix, resulting in a higher accumulation of Gd-DTPA.
In practical terms, following administration of a bolus of
Gd-DTPA, an inversion recovery sequence is performed, with
the inversion time (TI) set manually by the operator. The TI is
set in order to null “normal” remote myocardium which then
appears black, resulting in the greatest image intensity differ-
ence between normal and infarcted tissue [18]. This late
gadolinium enhancement (LGE) enables direct quantification
of the spatial extent of focal scar, but the ability for absolute
quantification of either diffuse, background fibrosis or density
of focal scar is lost. Despite the extremely high resolution and
correlation between histology and LGE in ex-vivo rat hearts at
high field strength [19••], it remains unknown what the clin-
ical minimum “critical mass” of collagen is for LGE detection
by. LGE imaging and analysis relies on thresholding tech-
niques for quantification. Depending on the disease and tech-
nique, there can be a two-fold difference [20]. New T1 map-
ping sequences, which will be discussed later, allow objective
quantification of signal magnitude, which is potentially direct-
ly comparable between studies and patients (Fig. 1).
Histological Basis of Scar Imaging by CMR
Initial animal work in the 1980s was performed with manga-
nese chloride [21] and later gadolinium chelates in canine
models of myocardial infarction showing differential and
time-varying effects on relaxation times of normal and infarct-
ed myocardium [22, 23]. The development of inversion re-
covery late gadolinium enhancement (LGE) MRI [24] and
extensive preclinical and clinical validation studies
established MRI as a reference standard method for imaging
myocardial infarction and viability. Kim et al. published a
seminal canine infarct study that documented that
gadolinium-enhanced MRI depicted infarcted myocardium
with remarkable fidelity [25]. That work was supported by
extensive validations of gadolinium concentrations in acutely
infarcted myocardium [26]. Careful studies resolved infarct
from the ARR and remote myocardium to determine that
gadolinium enhances acute and chronic MI [27]. The histo-
logical validation of LGE has been taken close to a cellular
level by Schelbert et al., who performed extremely high
resolution ex-vivo LGE imaging on rats at 7 Tesla and com-
pared with histological sections showing a remarkable corre-
lation (R2=0.96; p<0.001 – see Fig. 2) [19••].
Clinical validation studies established that gadolinium dif-
ferentiated viable myocardium from infarcted myocardium in
patients. Kim et al. showed that the transmural extent of
infarction predicted the recovery of contractile function after
revascularization [28], a study confirmed by Selvanayagam
et al. [29] – provided revascularization did not induce infarc-
tion. LGE-CMR has now become the gold standard for non-
invasive quantification of focal fibrosis, in particular infarct
size, with the spatial resolution needed to determine the
transmural extent of infarction. The burden of LGE predicts
function recovery after MI [30] and revascularization [29], as
well as mortality andMACE [31–33]. Single-photon emission
tomography (SPECT) and positron-emission tomography
(PET) validation studies confirmed that CMR LGE had equal
or better sensitivity for infarction [34], in particular in small
subendocardial infarctions seen on histology [35].
The LGE method has proved to be reproducible [36], and
was robust enough to perform with high sensitivity and spec-
ificity in a multicenter clinical trial [37]. LGE has therefore
established itself as the gold standard method for assessment
of scar in both ischemic and non ischemic heart diseases
including cardiomyopathy [38], myocarditis [39], aortic ste-
nosis induced pressure-overload hypertrophy [40] and infil-
trative diseases [41].
Advanced Scar Imaging and ECV
The extracellular matrix constitutes around 6 % of the normal
heart and serves to anchor cardiac muscle cells, thus determin-
ing cardiac structure and function [2]. As described, the LGE
technique is the gold standard for the assessment of focal
fibrosis [42, 43]. However, LGE is not able to quantify diffuse
myocardial fibrosis, which causes non-focal expansion of the
Curr Cardiovasc Imaging Rep (2014) 7:9254 Page 3 of 9, 9254
extracellular space. The current gold standard test for
quantifiying fibrosis is myocardial biopsy, but this is associated
with the potential for significant morbidity and mortality and is
also prone to sampling error [44]. Surrogate tests lack
sensitivity and/or specificity. New techniques for the quantifi-
cation of the extracellular space have therefore been developed.
Early in-vitro CMR work by Kehr et al. on human myo-
cardium obtained postmortem compared T1 values, calculated
Fig. 1 Multi-parametric imaging
in acute myocardial infarction.
Basal short axis slice in a patient
scanned 3 days after acute inferior
myocardial infarction. Native
(ShMOLLI [54•]) T1 maps (a)
and T2 maps (b) show elevated
values in the area-at-risk
(myocardium between double
lines); an ECV map (c) shows the
highest ECV values
corresponding to the area of late
gadolinium enhancement (d) or
acute infarction. Intra-myocardial
hemorrhage can be identified by
low T2 values in the core of the
risk zone (thin black arrow). A
small area of microvascular
obstruction in (d) does not allow
contrast to enter and appears as a
core of low ECV values in (c)
(thin white arrows)
Fig. 2 Histology and late
gadolinium enhancement images
in a rat model. Late gadolinium
enhancement (LGE) tracks
fibrosis to nearly the cellular level
in this post infarction ex-vivo rat
heart. LGE images were taken
ex-vivo at 7 Tesla with a 3D
gradient echo sequence (a and b)
were compared with histological
sections stained with Masson
trichrome (c-e). Adapted from
Schelbert et al. Circulation CVI
2010 [19••]
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from the inversion recovery signal curves, with collagen vol-
ume fraction, determined by the picrosirius red method, and
showed a significant correlation between the two methods
[45]. Flett et al. then developed an extracellular volume tech-
nique and validated it in patients with severe aortic stenosis
and hypertrophic cardiomyopathy [46••]: by calculating pre-
and post-contrast T1 values from inversion recovery sig-
nal curves, the extracellular volume fraction (ECV) was
derived by incorporating the blood volume of distribu-
tion (1-hematocrit). The ECV showed a high correlation
with the collagen volume fraction of biopsies obtained intra-
operatively in this cohort. This work has been replicated in
transplant hearts, shorter protocols and with newer, faster T1
mapping sequences (see Fig. 3) [47, 48]. After administration
of gadolinium, T1 is dominated by and inversely proportional
to the amount of gadolinium present in a tissue. Mea-
suring T1 after contrast provides a value linked to the
interstitium and has been applied to patients with heart
failure [49], but post-contrast T1 also varies with gadolinium
dose, time post bolus, and importantly patient specific factors
such as heart rate, clearance rate, body composition, and he-
matocrit. If the change in T1 pre- and post-contrast is measured
in both blood and myocardium after equilibration of the con-
trast distribution, the partition coefficient can be calculated. By
correcting for the hematocrit, the myocardial extracellular vol-
ume (ECV) is derived – a more stable and biologically signif-
icant biomarker. ECV divides the myocardium into two com-
partments (extracellular and cellular), and allows therefore non-
invasive quantification of the myocardial interstitial volume
and its reciprocal, cell volume; there is even some evidence
that the contrast kinetics could be used to obtain cell size-
dependent parameters [50]. The emerging evidence suggests
that ECVmeasurement is the more robust parameter [51••] and
the first of a new raft of papers on prognosis showing that ECV,
in unselected patients, predicts outcomes at least as strongly as
left ventricular ejection fraction [52••, 53].
Fig. 3 Histological validation of
diffuse fibrosis in severe aortic
stenosis. Top panel (a) showing
correlation of extracellular
volume (ECV) measured by
CMR with histological collagen
volume fraction in patients with
severe aortic stenosis. The dashed
lines represent 95 % confidence
intervals. Bottom row (b-d)
showing histology samples of
mild (b), moderate (c) and severe
(d) diffuse myocardial fibrosis.
Picrosirus red stains collagen
(fibrosis) red/pink, and counter
stains myocytes yellow. Collagen
volume fraction (%) was
calculated by automated
subtraction of these 2 color stains.
Adapted from White et al. JACC
CVI 2013 [47]
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From Signal Intensity to Direct Quantification –
Pixel-by-Pixel Mapping
The T1 mapping field is rapidly advancing, and advances
have brought it close to being used in clinical practice:
Single breath-hold mapping with MOLLI, ShMOLLI and
SASHA sequences [54•, 55•, 56•] (where each pixel
carries the T1 value) have replaced previous multi
breath-hold methods. Newer refinements include shorter
breath-holds, better sequence design, and lately, ECV
maps with pixel-by-pixel representation of ECV for a
simplified detection and quantitative display of focal
and diffuse fibrosis (see Fig. 1) [57••]. There is an
apparent spectrum of interstitial expansion with cardiac
amyloid, aortic stenosis and cardiomyopathy having large
changes in ECV; but age and gender have much smaller
or possibly no contributions [58] once partial volume
issues are accounted for. The ratio of pathophysiological
signal to measurement error is a key determinant of test
performance. T1 mapping appears especially robust in
detecting disease characterized by high ECV, such as
amyloid (where the ECV is often >0.5) [59], or marked
native T1 contrast diseases such as Anderson-Fabry dis-
ease (where fat storage makes native T1 fall) [60]. Little
biopsy histological correlation is available in these dis-
eases however. Native T1 mapping has also been used
for identification of diffuse myocardial fibrosis in aortic
stenosis and non-ischaemic cardiomyopathies [61, 62], as
well as the detection of acute myocarditis and showed
excellent and superior diagnostic performance compared
with T2-weighted CMR [63].
A key task will be to transition from an early develop-
ment phase with competing methodologies, to more stan-
dardized methodologies sufficient for use to: diagnose
disease; define mechanistic pathways of disease affecting
the interstitium, the myocyte or both; change therapy; and
employ ECV as a surrogate endpoint in trials of drug
development. This is the aim underpinning the recently
formed T1 mapping development group and the T1 map-
ping consensus statement [64••]. The consensus statement
also highlights that we are currently using a simple model
to explain far more complex in-vivo biological and molec-
ular structure: the interaction between cardiac myocytes
and the cardiac interstitium. Effects such as magnetization
transfer, diffusion distance and time, contrast mechanisms,
trans-cytolemmal water exchange rate, flow, T2 or T2*
relaxation will require further investigation [65, 66].
Other Techniques
A new approach is trying to exploit the signal from collagen-
related water molecules, which have a very fast signal decay
(short T2 and T2*) compared to water in soft tissue. Using
ultra short echo time (UTE) MRI, this has been success-
fully applied to solid collagen-rich areas like ligaments
and tendons. In a rat model of myocardial infarction,
UTE was able to directly detect post-infarct fibrosis
without the use of contrast agents [67]. Furthermore,
myocardial tissue characterization with quantification of
the extracellular space has also been performed with
cardiac computed tomography – in dogs [68] and humans
[69, 70] – and may be attractive, despite the radiation
dose, as it theoretically allows whole heart ECV quanti-
fication, although currently the technique has high noise
compared to CMR.
Conclusion
Using the fundamental T1 and T2 properties of myocar-
dial tissue as well as the highly reproducible post-
contrast LGE method, CMR has established itself as the
gold standard for non-invasive myocardial tissue charac-
terization. ECV diffuse fibrosis measurement may take
this a step further. We can now dichotomize the myocar-
dium into its cellular and interstitial components and this
will advance understanding of disease mechanisms as
well as their relative contribution to cardiac vulnerability.
This is a critically important issue, especially in the
setting of heart failure where drug development strategies
have produced few positive results over the last decade
[71]. CMR offers an array of techniques, which separate-
ly or in combination can detect and quantify early and
established myocardial pathological processes permitting
better diagnosis, prognostication and tracking of therapy.
This should in turn optimize the choice and timing of
interventions, and enhance drug development.
Acknowledgments T.A. Treibel is supported by a grant from the UK
National Institute for Health Research (Doctoral Research Training Fel-
lowship: DRF-2013-06-102). S.K. White is supported by a grant from the
British Heart Foundation (Clinical Research Training Fellowship: FS/ 10/
72/28568). J.C. Moon is supported by the Higher Education Funding
Council for England. This work was undertaken at the University College
London Hospital and University College London, which received a pro-
portion of funding from the Department of Health’s National Institute for
Health Research Biomedical Research Centres funding scheme.
Compliance with Ethics Guidelines
Conflict of Interest Thomas ATreibel, Steven K White, and James C
Moon declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
9254, Page 6 of 9 Curr Cardiovasc Imaging Rep (2014) 7:9254
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Anderson KR, Sutton MG, Lie JT. Histopathological types of
cardiac fibrosis in myocardial disease. J Pathol. 1979;128(2):79–
85. doi:10.1002/path.1711280205.
2. Rossi MA. Pathologic fibrosis and connective tissue matrix in left
ventricular hypertrophy due to chronic arterial hypertension in
humans. J Hypertens. 1998;16(7):1031–41.
3. Weber KT, Brilla CG. Myocardial fibrosis and the renin-
angiotensin-aldosterone system. J Cardiovasc Pharmacol. 1992;20
Suppl 1:S48–54.
4. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola
E, et al. Structural basis of end-stage failure in ischemic cardiomy-
opathy in humans. Circulation. 1994;89(1):151–63.
5. Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P,
Kaufman L, et al. Nuclear magnetic resonance imaging of acute
myocardial infarction in dogs: alterations in magnetic relaxation
times. Am J Cardiol. 1983;52(1):184–8.
6. Garcia-Dorado D, Oliveras J, Gili J, Sanz E, Perez-Villa F, Barrabes
J, et al. Analysis of myocardial oedema by magnetic resonance
imaging early after coronary artery occlusion with or without re-
perfusion. Cardiovasc Res. 1993;27(8):1462–9.
7. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt Jr
RF, et al. Retrospective determination of the area at risk for reper-
fused acute myocardial infarction with T2-weighted cardiac mag-
netic resonance imaging: histopathological and displacement
encoding with stimulated echoes (DENSE) functional validations.
Circula t ion. 2006;113(15) :1865–70. doi :10 .1161/
CIRCULATIONAHA.105.576025.
8. Tilak GS, Hsu LY, Hoyt Jr RF, Arai AE, Aletras AH. In vivo T2-
weighted magnetic resonance imaging can accurately determine the
ischemic area at risk for 2-day-old nonreperfused myocardial in-
farction. Invest Radiol. 2008;43(1):7–15. doi:10.1097/RLI.
0b013e3181558822.
9. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, et al.
Myocardial edema as detected by pre-contrast T1 and T2 CMR
delineates area at risk associated with acute myocardial infarction.
JACC Cardiovasc Imaging. 2012;5(6):596–603. doi:10.1016/j.
jcmg.2012.01.016.
10. Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ,
Messroghli D, Kumar A, et al. Delayed enhancement and T2-
weighted cardiovascular magnetic resonance imaging differen-
tiate acute from chronic myocardial infarction. Circulation.
2004;109(20):2411–6. doi:10.1161/01.CIR.0000127428.
10985.C6.
11. Berry C, Kellman P, Mancini C, Chen MY, Bandettini WP, Lowrey
T, et al. Magnetic resonance imaging delineates the ischemic area at
risk and myocardial salvage in patients with acute myocardial
infarction. Circ Cardiovasc Imaging. 2010;3(5):527–35. doi:10.
1161/CIRCIMAGING.109.900761.
12. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J,
Messroghli D, Dietz R. The salvaged area at risk in reperfused
acute myocardial infarction as visualized by cardiovascular mag-
netic resonance. J Am Coll Cardiol. 2008;51(16):1581–7. doi:10.
1016/j.jacc.2008.01.019.
13. Carlsson M, Ubachs JF, Hedstrom E, Heiberg E, Jovinge S,
Arheden H. Myocardium at risk after acute infarction in humans
on cardiac magnetic resonance: quantitative assessment during
follow-up and validation with single-photon emission computed
tomography. JACC Cardiovasc Imaging. 2009;2(5):569–76. doi:
10.1016/j.jcmg.2008.11.018.
14. Dall'Armellina E, Karia N, Lindsay AC, Karamitsos TD, Ferreira V,
RobsonMD, et al. Dynamic changes of edema and late gadolinium
enhancement after acute myocardial infarction and their relation-
ship to functional recovery and salvage index. Circ Cardiovasc
Imaging. 2011;4(3):228–36. doi:10.1161/CIRCIMAGING.111.
963421.
15. Nair V, Butany J. Heart transplant biopsies: interpretation and
significance. J Clin Pathol. 2010;63(1):12–20. doi:10.1136/jcp.
2009.072462.
16. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA
kinetics determineMRI contrast enhancement and reflect the extent
and severity of myocardial injury after acute reperfused infarction.
Circulation. 1996;94(12):3318–26.
17. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the
gadopentetate dimeglumine partition coefficient in human myocar-
dium in vivo: normal distribution and elevation in acute and
chronic infarction. Radiology. 2001;218(3):703–10.
18. Kim RJ, Shah DJ, Judd RM. How we perform delayed enhance-
ment imaging. J Cardiovasc Magn Reson. 2003;5(3):505–14.
19.•• Schelbert EB, Hsu LY, Anderson SA, Mohanty BD, Karim SM,
Kellman P, et al. Late gadolinium-enhancement cardiac magnetic
resonance identifies postinfarction myocardial fibrosis and the bor-
der zone at the near cellular level in ex vivo rat heart. Circ
Cardiovasc Imaging. 2010;3(6):743–52. doi:10.1161/
CIRCIMAGING.108.835793. The authors have taken histological
validation of LGE close to a cellular level, performing extremely
high-resolution ex-vivo LGE imaging on rats at 7 Tesla and com-
pared with histological sections showing a remarkable correlation.
20. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, et al.
Evaluation of techniques for the quantification of myocardial scar
of differing etiology using cardiac magnetic resonance. JACC
Cardiovasc Imaging. 2011;4(2):150–6. doi:10.1016/j.jcmg.2010.
11.015.
21. Goldman MR, Brady TJ, Pykett IL, Burt CT, Buonanno FS, Kistler
JP, et al. Quantification of experimental myocardial infarction using
nuclear magnetic resonance imaging and paramagnetic ion contrast
enhancement in excised canine hearts. Circulation. 1982;66(5):
1012–6.
22. Wesbey GE, Higgins CB, McNamara MT, Engelstad BL, Lipton
MJ, Sievers R, et al. Effect of gadolinium-DTPA on the magnetic
relaxation times of normal and infarcted myocardium. Radiology.
1984;153(1):165–9.
23. WesbeyG, Higgins CB, Lanzer P, Botvinick E, LiptonMJ. Imaging
and characterization of acute myocardial infarction in vivo by gated
nuclear magnetic resonance. Circulation. 1984;69(1):125–30.
24. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy
JM, et al. An improvedMR imaging technique for the visualization
of myocardial infarction. Radiology. 2001;218(1):215–23.
25. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O,
et al. Relationship of MRI delayed contrast enhancement to irre-
versible injury, infarct age, and contractile function. Circulation.
1999;100(19):1992–2002.
26. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial
magnetic resonance imaging contrast agent concentrations after
reversible and irreversible ischemic injury. Circulation.
2002;105(2):224–9.
27. Fieno DS, Kim RJ, Chen EL, Lomasney JW, Klocke FJ, Judd RM.
Contrast-enhanced magnetic resonance imaging of myocardium at
risk: distinction between reversible and irreversible injury through-
out infarct healing. J Am Coll Cardiol. 2000;36(6):1985–91.
28. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al.
The use of contrast-enhanced magnetic resonance imaging to iden-
tify reversible myocardial dysfunction. N Engl J Med.
2000;343(20):1445–53. doi:10.1056/NEJM200011163432003.
Curr Cardiovasc Imaging Rep (2014) 7:9254 Page 7 of 9, 9254
29. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen
SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular
magnetic resonance imaging in predictingmyocardial viability after
surgical revascularization. Circulation. 2004;110(12):1535–41. doi:
10.1161/01.CIR.0000142045.22628.74.
30. Choi KM, KimRJ, Gubernikoff G, Vargas JD, Parker M, Judd RM.
Transmural extent of acute myocardial infarction predicts long-term
improvement in contractile function. Circulation. 2001;104(10):
1101–7.
31. Yan AT, Shayne AJ, Brown KA, Gupta SN, Chan CW, Luu TM,
et al. Characterization of the peri-infarct zone by contrast-enhanced
cardiac magnetic resonance imaging is a powerful predictor of post-
myocardial infarction mortality. Circulation. 2006;114(1):32–9.
doi:10.1161/CIRCULATIONAHA.106.613414.
32. KwongRY, ChanAK,BrownKA,ChanCW,ReynoldsHG, Tsang S,
et al. Impact of unrecognized myocardial scar detected by cardiac
magnetic resonance imaging on event-free survival in patients present-
ing with signs or symptoms of coronary artery disease. Circulation.
2006;113(23):2733–43. doi:10.1161/CIRCULATIONAHA.105.
570648.
33. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P,
et al. Infarct size by contrast enhanced cardiac magnetic resonance
is a stronger predictor of outcomes than left ventricular ejection
fraction or end-systolic volume index: prospective cohort study.
Heart. 2008;94(6):730–6. doi:10.1136/hrt.2007.122622.
34. Klein C, Nekolla SG, Balbach T, Schnackenburg B, Nagel E, Fleck
E, et al. The influence of myocardial blood flow and volume of
distribution on late Gd-DTPA kinetics in ischemic heart failure. J
Magn Reson Imaging. 2004;20(4):588–93. doi:10.1002/jmri.20164.
35. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M,
Parker M, et al. Contrast-enhanced MRI and routine single photon
emission computed tomography (SPECT) perfusion imaging for
detection of subendocardial myocardial infarcts: an imaging study.
Lancet. 2003;361(9355):374–9. doi:10.1016/s0140-6736(03)
12389-6.
36. Mahrholdt H, Wagner A, Holly TA, Elliott MD, Bonow RO, Kim
RJ, et al. Reproducibility of chronic infarct size measurement by
contrast-enhanced magnetic resonance imaging. Circulation.
2002;106(18):2322–7.
37. Kim RJ, Albert TS, Wible JH, Elliott MD, Allen JC, Lee JC, et al.
Performance of delayed-enhancement magnetic resonance imaging
with gadoversetamide contrast for the detection and assessment of
myocardial infarction: an international, multicenter, double-
blinded, randomized trial. Circulation. 2008;117(5):629–37. doi:
10.1161/CIRCULATIONAHA.107.723262.
38. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD,
Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly
symptomatic patients with hypertrophic cardiomyopathy. J Am
Coll Cardiol. 2002;40(12):2156–64.
39. Wagner A, Schulz-Menger J, Dietz R, Friedrich MG. Long-term
follow-up of patients paragraph sign with acute myocarditis by
magnetic paragraph sign resonance imaging. Magma. 2003;16(1):
17–20. doi:10.1007/s10334-003-0007-7.
40. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina
G, et al. Midwall fibrosis is an independent predictor of mortality in
patients with aortic stenosis. J AmColl Cardiol. 2011;58(12):1271–
9. doi:10.1016/j.jacc.2011.03.064.
41. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ.
Cardiovascular magnetic resonance and prognosis in cardiac amy-
loidosis. J CardiovascMagnReson. 2008;10:54. doi:10.1186/1532-
429X-10-54.
42. Zemrak F, Petersen SE. Late gadolinium enhancement CMR pre-
dicts adverse cardiovascular outcomes and mortality in patients
with coronary artery disease: systematic review and meta-
analysis. Prog Cardiovasc Dis. 2011;54(3):215–29. doi:10.1016/j.
pcad.2011.07.003.
43. Ismail TF, Prasad SK, Pennell DJ. Prognostic importance of late
gadolinium enhancement cardiovascular magnetic resonance in
cardiomyopathy. Heart. 2012;98(6):438–42. doi:10.1136/heartjnl-
2011-300814.
44. Becker AE, Heijmans CD, Essed CE. Chronic non-ischaemic con-
gestive heart disease and endomyocardial biopsies.Worth the extra?
Eur Heart J. 1991;12(2):218–23.
45. Kehr E, Sono M, Chugh SS, Jerosch-Herold M. Gadolinium-
enhanced magnetic resonance imaging for detection and quantifi-
cation of fibrosis in human myocardium in vitro. Int J Cardiovasc
Imaging. 2008;24(1):61–8. doi:10.1007/s10554-007-9223-y.
46.•• Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM,
Elliott PM, et al. Equilibrium contrast cardiovascular magnetic
resonance for the measurement of diffuse myocardial fibrosis:
preliminary validation in humans. Circulation. 2010;122(2):138–
44. doi:10.1161/CIRCULATIONAHA.109.930636. The authors
developed an extracellular volume technique and validated it
against histology in patients with severe aortic stenosis and
hypertrophic cardiomyopathy.
47. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V,
Flett AS, et al. T1 mapping for myocardial extracellular volume
measurement by CMR: bolus only versus primed infusion tech-
nique. JACC Cardiovasc Imaging. 2013. doi:10.1016/j.jcmg.2013.
01.011.
48. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al.
Comprehensive validation of cardiovascular magnetic resonance
techniques for the assessment of myocardial extracellular volume.
Circ Cardiovasc Imaging. 2013;6(3):373–83. doi:10.1161/
CIRCIMAGING.112.000192.
49. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta
SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure
with cardiac magnetic resonance contrast-enhanced T1 mapping. J
Am Coll Cardiol. 2008;52(19):1574–80. doi:10.1016/j.jacc.2008.
06.049.
50. Coelho-Filho OR, Shah RV, Mitchell R, Neilan TG, Moreno Jr H,
Simonson B, et al. Quantification of cardiomyocyte hypertrophy by
cardiac magnetic resonance: implications for early cardiac remod-
eling. Circulation. 2013;128(11):1225–33. doi:10.1161/
CIRCULATIONAHA.112.000438.
51.•• Ugander M, Oki AJ, Hsu LY, Kellman P, Greiser A, Aletras AH,
et al. Extracellular volume imaging by magnetic resonance imaging
provides insights into overt and sub-clinical myocardial pathology.
Eur Heart J. 2012;33(10):1268–78. doi:10.1093/eurheartj/ehr481.
The authors show that ECVimaging can quantitatively characterize
MI, atypical diffuse fibrosis, and subtle myocardial abnormalities
not clinically apparent on LGE images.
52.•• Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi
AA, et al. Association between extracellular matrix expansion
quantified by cardiovascular magnetic resonance and short-term
mortality. Circulation. 2012;126(10):1206–16. doi:10.1161/
CIRCULATIONAHA.111.089409. In this large cohort study,
the authors show in unselected patients that ECV predicts
outcomes at least as strongly as left ventricular ejection fraction.
53. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P,
Schwartzman DS, et al. Myocardial extracellular volume fraction
quantified by cardiovascular magnetic resonance is increased in
diabetes and associated with mortality and incident heart failure
admission. Eur Heart J. 2013. doi:10.1093/eurheartj/eht193.
54.• Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser
A, Neubauer S, et al. Shortened Modified Look-Locker Inversion
recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5
and 3 Twithin a 9 heartbeat breathhold. J Cardiovasc Magn Reson.
2010;12:69. doi:10.1186/1532-429X-12-69. A seminal papers for
the three main T1 mapping sequences.
55.• Messroghli DR, Radjenovic A, Kozerke S, Higgins DM,
Sivananthan MU, Ridgway JP. Modified Look-Locker inversion
9254, Page 8 of 9 Curr Cardiovasc Imaging Rep (2014) 7:9254
recovery (MOLLI) for high-resolution T1 mapping of the heart.
Magn Reson Med. 2004;52(1):141–6. doi:10.1002/mrm.20110. A
seminal paper for the three main T1 mapping sequences.
56.• Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG,
Thompson RB. Saturation recovery single-shot acquisition
(SASHA) for myocardial T mapping. Magn Reson Med. 2013.
doi:10.1002/mrm.24878. A seminal paper for the three main T1
mapping sequences.
57.•• Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular
volume fraction mapping in the myocardium, part 1: evaluation of an
automated method. J Cardiovasc Magn Reson. 2012;14:63. doi:10.
1186/1532-429X-14-63. In this work, the authors developed and
evaluated a fully automated, motion-corrected and co-registered meth-
od for producing ECV maps feasible for clinical work flow.
58. Sado DM, Flett AS, Banypersad SM, White SK, Maestrini V,
Quarta G, et al. Cardiovascular magnetic resonance measurement
of myocardial extracellular volume in health and disease. Heart.
2012;98(19):1436–41. doi:10.1136/heartjnl-2012-302346.
59. Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi
NB, Ferreira VM, et al. Noncontrast t1 mapping for the diagnosis of
cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6(4):488–
97. doi:10.1016/j.jcmg.2012.11.013.
60. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T,
Captur G, et al. The identification and assessment of anderson fabry
disease by cardiovascular magnetic resonance non-contrast myo-
cardial T1 mapping. Circ Cardiovasc Imaging. 2013. doi:10.1161/
CIRCIMAGING.112.000070.
61. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M,
et al. Human non-contrast T1 values and correlation with histology
in diffuse fibrosis. Heart. 2013;99(13):932–7. doi:10.1136/heartjnl-
2012-303052.
62. Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al.
Native T1 mapping in differentiation of normal myocardium from
diffuse disease in hypertrophic and dilated cardiomyopathy. JACC
Cardiovasc Imaging. 2013;6(4):475–84. doi:10.1016/j.jcmg.2012.
08.019.
63. Ferreira VM, Piechnik SK, Dall'armellina E, Karamitsos TD,
Francis JM, Ntusi N, et al. T mapping for the diagnosis of acute
myocarditis using CMR: comparison to T-weighted and late gado-
linium enhanced imaging. JACC Cardiovasc Imaging. 2013. doi:
10.1016/j.jcmg.2013.03.008.
64.•• Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD,
Ugander M, et al. Myocardial T1mapping and extracellular volume
quantification: a Society for Cardiovascular Magnetic Resonance
(SCMR) and CMR Working Group of the European Society of
Cardiology consensus statement. J Cardiovasc Magn Reson.
2013;15(1):92. doi:10.1186/1532-429X-15-92. This document
provides recommendations for clinical and research T1 and ECV
measurement, addressing site preparation, scan type, scan
planning and acquisition, quality control, visualisation and
analysis, technical development, as well as discussing
controversies in the field.
65. Robson MD, Piechnik SK, Tunnicliffe EM, Neubauer S. T mea-
surements in the human myocardium: the effects of magnetization
transfer on the SASHA and MOLLI sequences. Magn Reson Med.
2013. doi:10.1002/mrm.24867.
66. Coelho-Filho OR, Mongeon FP, Mitchell R, Moreno Jr H, Nadruz
Jr W, Kwong R, et al. Role of transcytolemmal water-exchange in
magnetic resonance measurements of diffuse myocardial fibrosis in
hypertensive heart disease. Circ Cardiovasc Imaging. 2013;6(1):
134–41. doi:10.1161/CIRCIMAGING.112.979815.
67. de Jong S, Zwanenburg JJ, Visser F, der Nagel R, van Rijen
HV, Vos MA, et al. Direct detection of myocardial fibrosis
by MRI. J Mol Cell Cardiol. 2011;51(6):974–9. doi:10.1016/
j.yjmcc.2011.08.024.
68. Ugander MC, Chen MY, Chen B, Bagi PS, Hsu LY, Kellman
P, Arai AE. Contrast Enhanced CT and MRI Measures of
Extracellular Volume Fraction Confirm Presence of Peri-
Infarct Edema in Acute Myocardial Infarction (Abstract).
American Heart Association 2011.
69. Bandula S, White SK, Flett AS, Lawrence D, Pugliese F,
Ashworth MT, et al. Measurement of myocardial extracellular
volume fraction by using equilibrium contrast-enhanced CT:
validation against histologic findings. Radiology. 2013. doi:
10.1148/radiol.13130130.
70. Nacif MS, Kawel N, Lee JJ, Chen X, Yao J, Zavodni A, et al.
Interstitial myocardial fibrosis assessed as extracellular volume
fraction with low-radiation-dose cardiac CT. Radiology.
2012;264(3):876–83. doi:10.1148/radiol.12112458.
71. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportuni-
ties for drug development in heart failure. Jama. 2013;309(15):
1593–4. doi:10.1001/jama.2013.1063.
Curr Cardiovasc Imaging Rep (2014) 7:9254 Page 9 of 9, 9254
